Show simple item record

dc.contributor.authorÁlvarez García, Francisco José
dc.contributor.authorCilleruelo Ortega, María José
dc.contributor.authorÁlvarez Aldeán, Javier
dc.contributor.authorGarcés Sánchez, María
dc.contributor.authorGarcía Sánchez, Nuria
dc.contributor.authorGarrote Llanos, Elisa
dc.contributor.authorHernández Merino, Ángel
dc.contributor.authorIofrío de Arce, Antonio
dc.contributor.authorMontesdeoca Melián, Abián
dc.contributor.authorNavarro Gómez, María Luisa
dc.contributor.authorRuiz Contreras, Jesús
dc.contributor.authorComité Asesor de Vacunas de la Asociación Española de Pediatría
dc.date.accessioned2021-03-01T13:08:53Z
dc.date.available2021-03-01T13:08:53Z
dc.date.issued2021-01
dc.identifier.citationAnales de pediatría 94(1) : 53.e1-53.e10 (2021)es_ES
dc.identifier.issn1695-9531
dc.identifier.urihttp://hdl.handle.net/10810/50395
dc.description.abstractThe CAV-AEP annually publishes the immunisation schedule considered optimal for all children and adolescent resident in Spain, taking into account the available evidence. The 2+1 schedule is recommended (2, 4, and 11 months) with hexavalent vaccines (DTPa-VPI-Hib-HB) and with 13-valent pneumococcal conjugate.A 6-year booster is recommended, preferably with DTPa (if available), with a dose of polio for those who received 2+1 schemes, as well as vaccination with Tdpa in adolescents and in each pregnancy, preferably between 27 and 32 weeks. Rotavirus vaccine should be systematic for all infants. Meningococcal B vaccine, with a 2+1 schedule, should be included in routine calendar. In addition to the inclusion of the conjugated tetravalent meningococcal vaccine (MenACWY) at 12 years of age with catch up to 18 years, inclusive, the CAV recommends this vaccine to be also included at 12 months of age, replacing MenC. Likewise, it is recommended in those over 6 weeks of age with risk factors or who travel to countries with a high incidence of these serogroups. Two-dose schedules for triple viral (12 months and 3-4 years) and varicella (15 months and 3-4 years) will be used. The second dose could be applied as a tetraviral vaccine. Universal systematic vaccination against HPV is recommended, regardless of gender, preferably at 12 years, and greater effort should be made to improve coverage. The 9 genotype extends coverage for both genders.es_ES
dc.language.isoenges_ES
dc.publisherAsociación Española de Pediatríaes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectadolescentes_ES
dc.subjectadolescentees_ES
dc.subjectcalendario de vacunaciónes_ES
dc.subjectchildes_ES
dc.subjectenfermedades inmunoprevenibleses_ES
dc.subjectimmunisation schedulees_ES
dc.subjectinfantes_ES
dc.subjectlactantees_ES
dc.subjectniñoes_ES
dc.subjectvaccine preventable diseaseses_ES
dc.subjectvaccineses_ES
dc.subjectvacunases_ES
dc.titleCalendario de vacunaciones de la Asociación Española de Pediatría: recomendaciones 2021es_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder2020 Asociación Española de Pediatría. Publicado por Elsevier. Bajo una licencia CC Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)es_ES
dc.rights.holderAtribución-NoComercial-SinDerivadas 3.0 España*
dc.relation.publisherversionhttps://www.analesdepediatria.org/es-linkresolver-calendario-vacunaciones-asociacion-espanola-pediatria-S1695403320304409es_ES
dc.identifier.doi10.1016/j.anpedi.2020.10.002
dc.departamentoesPediatríaes_ES
dc.departamentoeuPediatriaes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

2020 Asociación Española de Pediatría. Publicado por Elsevier. Bajo una licencia CC Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Except where otherwise noted, this item's license is described as 2020 Asociación Española de Pediatría. Publicado por Elsevier. Bajo una licencia CC Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)